Abstract:Triple negative breast cancer (TNBC) is a subtype of breast cancer (BC) that makes up 10–15% of BC diagnosis. This form of the disease disproportionately affects African American (AA) women as compared to women of other ethnicities. TNBC is classified by lack of expression of three receptors: Estrogen alpha (ERα), progesterone (PR) and human epidermal growth factor 2 (HER2). These receptors are used as therapeutic targets for BC that express them. As specific targets are not present, surgery, radiation and chemotherapy have been the mainstay of therapy for TNBC. Recently, newer drugs have become available based on specific genetic and epigenetic mutations like BRCA1, however more treatment options need to be produced to reduce the mortality rate in this disease. A novel compound, 2, 3‐dichloro‐5, 8‐dimethoxy‐1, 4‐naphthoquinone (Z285) belongs to the class of naphthoquinones that demonstrate activities as anticancer, antimalarial, and antibacterial compounds. These compounds have also been shown to cause an increase in reactive oxygen species (ROS) production as well as affect signaling pathways associated with epidermal growth factor receptor (EGFR). Moreover, it has been reported that treatment with tamoxifen can cause cell death. This is based on the accumulation of the drug and its active metabolites within cells that may cause an increase in the ROS production ultimately leading to cellular death, even in ERα negative cell lines. In the current study, three triple negative cell lines, HCC1806, MDA MB 231 and HS578T were used. These cells were treated with Z285 and 4‐hydroxy tamoxifen (4OH‐Tam) for 24 or 72hr with 1, 2, 4, 8, 16μM and 3, 6, 12, 24, 48μM respectively. Synergestic activity was demonstrated using SynergyFinder as well as the Chou‐Talalay method (CompuSyn). In other experiments, cells were treated with the IC50 of Z285 which was established in prior experiments. mRNA and protein were isolated between 6 and 24hr. Results showed alterations of several mRNA in response to these treatments. In addition, there were modifications to Nrf2 protein concentration, a transcription factor associated with oxidative stress. Therefore, these results indicate that combination treatment of Z285 and 4OH‐Tam induce cell death at lower concentrations. Thus this novel compound which causes an increase in ROS in these TNBC cells, may render them more susceptible to tamoxifen therapy. Charles and Mary Latham Fund

Naphthoquinone-derived ZSW-4B induces apoptosis in triple-negative breast cancer via AMPK signalling activation

Apatinib-induced NF-κB Inactivation Sensitizes Triple-Negative Breast Cancer Cells to Doxorubicin.

Zingerone Facilitates Apoptosis in Triple Negative Breast Cancer Cells by Inducing Autophagy

Decreased Cell Proliferation with 2, 3‐ Dichloro‐5, 8‐Dimethoxy‐1, 4‐Naphthoquinone and 4‐Hydroxy Tamoxifen in Triple Negative Breast Cancer Cell Lines

N-((1-(4-Fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-2-methylene-3-oxo-olean-12-en-28-amide Induces Apoptosis in Human Breast Cancer Cells by Stimulating Oxidative Stress and Inhibiting the Notch-Akt Signaling Pathway

Knockdown of TAZ Modifies Triple-Negative Breast Cancer Cell Sensitivity to EGFR Inhibitors by Regulating YAP Expression.

A novel methuosis inducer DZ-514 possesses antitumor activity via activation of ROS-MKK4-p38 axis in triple negative breast cancer

CSC-3436 switched tamoxifen-induced autophagy to apoptosis through the inhibition of AMPK/mTOR pathway

TQFL12, a novel synthetic derivative of TQ, inhibits triple-negative breast cancer metastasis and invasion through activating AMPK/ACC pathway

Energy Stress-activated AMPK Phosphorylates Snail1 and Suppresses Its Stability and Oncogenic Function

4-Acetylantroquinonol B induced DNA damage response signaling and apoptosis via suppressing CDK2/CDK4 expression in triple negative breast cancer cells

Anti-migration and anti-invasion effects of 2-hydroxy-6-tridecylbenzoic acid is associated with the enhancement of CYP1B1 expression through activating the AMPK signaling pathway in triple-negative breast cancer cells

Knockdown of PC4 increases chemosensitivity of Oxaliplatin in triple negative breast cancer by suppressing mTOR pathway

Thioguanine Induces Apoptosis in Triple-Negative Breast Cancer by Regulating PI3K–AKT Pathway

Vertical pathway inhibition of receptor tyrosine kinases and BAD with synergistic efficacy in triple negative breast cancer

OSW-1 induces apoptosis and cyto-protective autophagy, and synergizes with chemotherapy on triple negative breast cancer metastasis

Identification of a novel PAK1/HDAC6 dual inhibitor ZMF-23 that triggers tubulin-stathmin regulated cell death in triple negative breast cancer

KK-LC-1 as a therapeutic target to eliminate ALDH+ stem cells in triple negative breast cancer

Synergistic effect of bazedoxifene and abemaciclib co‐treatment in triple‐negative breast cancer cells in vitro

Hippophae Rhamnoides-derived Phytomedicine Nano-System Modulates Bax/Fas Pathways to Reduce Proliferation in Triple-Negative Breast Cancer

Synthesis and mechanism of action of new purine derivatives against triple negative breast cancer